Cargando…
Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms?
SIMPLE SUMMARY: Over the last decade, the treatment of patients diagnosed with melanoma has transformed with the introduction of checkpoint inhibitors and targeted therapies. However, innate or acquired resistance, as well as toxicities of these treatments demands additional options for patients wit...
Autores principales: | Kakish, Hanna H., Ahmed, Fasih Ali, Elshami, Mohamedraed, Loftus, Alexander W., Hoehn, Richard S., Ammori, John B., Ocuin, Lee M., Winter, Jordan M., Bordeaux, Jeremy S., Mangla, Ankit, Rothermel, Luke D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658976/ https://www.ncbi.nlm.nih.gov/pubmed/36358601 http://dx.doi.org/10.3390/cancers14215184 |
Ejemplares similares
-
Racial differences in time to treatment for melanoma
por: Tripathi, Raghav, et al.
Publicado: (2020) -
The Impact of COVID-19 on Time-to-treatment in Pancreatic Adenocarcinoma: A Single Institutional Experience
por: Sugumar, Kavin, et al.
Publicado: (2021) -
The importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: A systematic review and meta‐analysis
por: Sugumar, Kavin, et al.
Publicado: (2021) -
Wild-type IDH1 inhibition enhances chemotherapy response in melanoma
por: Zarei, Mehrdad, et al.
Publicado: (2022) -
Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer
por: Hue, Jonathan J., et al.
Publicado: (2021)